Radiation therapy dose escalation for prostate cancer: A rationale for IMRT

World Journal of Urology

Volumn 21, Issue 4, 2003, Pages 200-208

  Pollack, Alan ^a   Hanlon, Alex ^a   Horwitz, Eric M ^a   Feigenberg, Steven ^a   Uzzo, Robert G ^a   Price, Robert A ^a  

^a FOX CHASE CANCER CENTER   (United States)

Author keywords

Dose escalation; Intensity modulated radiotherapy; Prostate cancer

Indexed keywords

HUMAN; MALE; METHODOLOGY; MORTALITY; PROSTATE TUMOR; RADIATION DOSE; RADIOTHERAPY; REVIEW;

HUMANS; MALE; PROSTATIC NEOPLASMS; RADIOTHERAPY; RADIOTHERAPY DOSAGE;

EID: 1542293746     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-003-0356-x     Document Type: Article

References (70)

1. Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H (1998) Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice. Mayo Clin Proc 73:401-406
2. Antolak J, Rosen I, Childress C, Zagars G, Pollack A (1998) Prostate target volume variations during a course of radiotherapy. Int J Radiat Oncol Biol Phys 42:661-672
3. Benk VA, Adams JA, Shipley WU, Urie MM, McManus PL, Efird JT, Willett CG, Goitein M (1993) Late rectal bleeding following combined x-ray and proton high dose irradiation for patients with stages T3-T4 prostate carcinoma. Int J Radiat Oncol Biol Phys 26:551-557
4. Boersma LJ, van den Brink M, Bruce AM, Shouman T, Gras L, te Velde A, Lebesque JV (1998) Estimation of the incidence of late bladder and rectum complications after high-dose (70-78 GY) conformal radiotherapy for prostate cancer, using dose-volume histograms. Int J Radiat Oncol Biol Phys 41:83-92
5. Brenner DJ, Hall EJ (1999) Fractionation and protraction for radiotherapy of prostate carcinoma. Int J Radiat Oncol Biol Phys 43:1095-1101
6. Brenner DJ, Martinez AA, Edmundson GK, Mitchell C, Thames HD, Armour EP (2002) Direct evidence that prostate tumors show high sensitivity to fractionation (low alpha/beta ratio), similar to late-responding normal tissue. Int J Radiat Oncol Biol Phys 52:6-13
7. Chandra A, Dong L, Huang E, Kuban DA, O'Niell L, Rosen I, Pollack A (2003) Experience of ultrasound-based daily prostate localization. Int J Radiat Oncol Biol Phys 56:436-447
8. Chism DB, Hanlon AL, Troncoso P, Al-Saleem T, Horwitz EM, Pollack A (2003) The Gleason score shift: score four and seven years ago. Int J Radiat Oncol Biol Phys 56:1241-1247
9. Cox J, Grignon D, Kaplan R, Parsons J, Schellhammer P (1997) Consensus statement: guidelines for PSA following radiation therapy. Int J Radiat Oncol Biol Phys 37:1035-1041
10. Critz FA, Williams WH, Holladay CT, Levinson AK, Benton JB, Holladay DA, Schnell FJ Jr, Maxa LS, Shrake PD (1999) Post-treatment PSA < or = 0.2 ng/mL defines disease freedom after radiotherapy for prostate cancer using modern techniques. Urology 54:968-971
11. Critz FA (2002) A standard definition of disease freedom is needed for prostate cancer: undetectable prostate specific antigen compared with the American Society of Therapeutic Radiology and Oncology consensus definition. J Urol 167:1310-1313
12. Crook J, Malone S, Perry G, Bahadur Y, Robertson S, Abdolell M (2000) Postradiotherapy prostate biopsies: what do they really mean? Results for 498 patients. Int J Radiat Oncol Biol Phys 48:355-367
13. Crook JM, Raymond Y, Salhani D, Yang H, Esche B (1995) Prostate motion during standard radiotherapy as assessed by fiducial markers. Radiother Oncol 37:35-42
14. D'Amico A, Whittington R, Malkowicz S, et al. (1998) Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 280:969-974
15. D'Amico AV, Chen MH, Oh-Ung J, Renshaw AA, Cote K, Loffredo M, Richie JP (2002) Changing prostate-specific antigen outcome after surgery or radiotherapy for localized prostate cancer during the prostate-specific antigen era. Int J Radiat Oncol Biol Phys 54:436-441
16. Dawson LA, Litzenberg DW, Brock KK, Sanda M, Sullivan M, Sandler HM, Balter JM (2000) A comparison of ventilatory prostate movement in four treatment positions. Int J Radiat Oncol Biol Phys 48:319-323
17. Dearnaley DP, Khoo VS, Norman AR, Meyer L, Nahum A, Tait D, Yarnold J, Horwich A (1999) Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: a randomised trial. Lancet 353:267-272
18. D'Souza WD, Thames HD (2001) Is the alpha/beta ratio for prostate cancer low? Int J Radiat Oncol Biol Phys 51:1-3
19. Fowler J, Chappell R, Ritter M (2001) Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 50:1021-1031
20. Gardner BG, Zietman AL, Shipley WU, Skowronski UE, McManus P (2002) Late normal tissue sequelae in the second decade after high dose radiation therapy with combined photons and conformal protons for locally advanced prostate cancer. J Urol 167:123-126
21. Hanks GE, Hanlon AL, Epstein B, Horwitz EM (2002) Dose response in prostate cancer with 8-12 years' follow-up. Int J Radiat Oncol Biol Phy 54:427-435
22. Hanks GE, Leibel SA, Krall JM, Kramer S (1985) Patterns of care studies: dose response observations for local control of adenocarcinoma of the prostate. Int J Radiat Oncol Biol Phys 11:153-157
23. Hanks GE (1988) External beam radiation therapy for clinically localized prostate cancer: patterns of care studies in the United States. NCI Monographs 7:75-84
24. Hanks GE, Martz KL, Diamond JJ (1988) The effect of dose on local control of prostate cancer. Int J Radiat Oncol Biol Phys 15:1299-1305
25. Hanks GE, Hanlon AL, Schultheiss TE, Pinover WH, Movsas B, Epstein BE, Hunt MS (1998) Dose escalation with 3D conformal treatment: five year outcomes, treatment optimization and future directions. Int J Radiat Oncol Biol Phys 41:501-510
26. Hanks G, Hanlon A, Pinover W, Horwitz E, Schultheiss T (1999) Survival advantage for prostate cancer patientstreated with high dose 3D conformal radiation. Cancer J Sci Am 5:152-158
27. Hanlon AL, Diratzouian H, Hanks GE (2002) Posttreatment prostate-specific antigen nadir highly predictive of distant failure and death from prostate cancer. Int J Radiat Oncol Biol Phys 53:297-303
28. Horwitz EM, Uzzo RG, Hanlon AL, Greenberg RE, Hanks GE, Pollack A (2003) Modifying the ASTRO definition of biochemical failure to minimize the influence of backdating in patients with prostate cancer treated with 3D conformal radiation therapy alone. J Urol 169:2153-2159
29. Hua C, Lovelock M, Mageras GS, Katz MS, Mechalakos J, Lief EP, Hollister T, Lutz WR, Zelefsky MJ, Ling CC (2003) Development of a semi-automatic alignment tool for accelerated localization of the prostate. Int J Radiat Oncol Biol Phys 55:811-824
30. Huang EH, Pollack A, Levy L, Starkschall G, Dong L, Rosen I, Kuban DA (2002) Late rectal toxicity: dose-volume effects of conformal radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 54:1314-1321
31. Huang E, Dong L, Chandra A, Kuban DA, Rosen II, Evans A, Pollack A (2002) Intrafraction prostate motion during IMRT for prostate cancer. Int J Radiat Oncol Biol Phys 53:261-268
32. Jaffray DA, Siewerdsen JH, Wong JW, Martinez AA (2002) Flat-panel cone-beam computed tomography for image-guided radiation therapy. Int J Radiat Oncol Biol Phys 53:1337-1349
33. Jhaveri FM, Klein EA, Kupelian PA, Zippe C, Levin HS (1999) Declining rates of extracapsular extension after radical prostatectomy: evidence for continued stage migration. J Clin Oncol 17:3167-3172
34. Kestin LL, Vicini FA, Martinez AA (2002) Practical application of biochemical failure definitions: what to do and when to do it. Int J Radiat Oncol Biol Phys 53:304-315
35. Kestin LL, Vicini FA, Ziaja EL, Stromberg JS, Frazier RC, Martinez AA (1999) Defining biochemical cure for prostate carcinoma patients treated with external beam radiation therapy. Cancer 86:1557-1566
36. Keyser D, Kupelian PA, Zippe CD, Levin HS, Klein EA (1997) Stage T1-2 prostate cancer with pretreatment prostate-specific antigen level < or = 10 ng/ml: radiation therapy or surgery?" Int J Radiat Oncol Biol Phys 38:723-729
37. King CR, Fowler JF (2001) A simple analytic derivation suggests that prostate cancer alpha/beta ratio is low. Int J Radiat Oncol Biol Phys 51:213-214
38. Kitamura K, Shirato H, Seppenwoolde Y, Onimaru R, Oda M, Fujita K, Shimizu S, Shinohara N, Harabayashi T, Miyasaka K (2002) Three-dimensional intrafractional movement of prostate measured during real-time tumor-tracking radiotherapy in supine and prone treatment positions. Int J Radiat Oncol Biol Phys 53:1117-1123
39. Kitamura K, Shirato H, Shimizu S, Shinohara N, Harabayashi T, Shimizu T, Kodama Y, Endo H, Onimaru R, Nishioka S, Aoyama H, Tsuchiya K, Miyasaka K (2002) Registration accuracy and possible migration of internal fiducial gold marker implanted in prostate and liver treated with real-time tumor-tracking radiation therapy (RTRT). Radiother Oncol 62:275-281
40. Kupelian PA, Buchsbaum JC, Patel C, Elshaikh M, Reddy CA, Zippe C, Klein EA (2002) Impact of biochemical failure on overall survival after radiation therapy for localized prostate cancer in the PSA era. Int J Radiat Oncol Biol Phys 52:704-711
41. Kupelian PA, Reddy CA, Carlson TP, Willoughby TR (2002) Dose/volume relationship of late rectal bleeding after external beam radiotherapy for localized prostate cancer: absolute or relative rectal volume? Cancer J 8:62-66
42. Kupelian PA, Reddy CA, Klein EA, Willoughby TR (2001) Short-course intensity-modulated radiotherapy (70 GY at 2.5 GY per fraction) for localized prostate cancer: preliminary results on late toxicity and quality of life. Int J Radiat Oncol Biol Phys 51:988-993
43. Kupelian PA, Willoughby TR (2001) Short-course, intensity-modulated radiotherapy for localized prostate cancer. Cancer J 7:421-426
44. Langen KM, Jones DT (2001) Organ motion and its management. Int J Radiat Oncol Biol Phys 50:265-278
45. Lattanzi J, McNeely S, Pinover W, Horwitz E, Das I, Price R, Schultheiss T, Hanks G (1999) A comparison of daily CT localization to a daily ultrasound-based system in prostate cancer. Int J Radiat Oncol Biol Phys 43:719-725
46. Lee WR, Hanks GE, Hanlon A, Schultheiss TE, Hunt MA (1996) Lateral rectal shielding reduces late rectal morbidity following high dose three-dimensional conformal radiation therapy for clinically localized prostate cancer: further evidence for a significant dose effect. Int J Radiat Oncol Biol Phys 35:251-257
47. Lyons J, Kupelian P, Mohan D, Reddy C, EA K (2000) Importance of high radiation doses (72 Gy or greater) in the treatment of stage T1-T3 adenocarcinoma of the prostate. Urology 55:85-90
48. Mah D, Freedman G, Milestone B, Hanlon A, Palacio E, Richardson T, Movsas B, Mitra R, Horwitz E, Hanks GE (2002) Measurement of intrafractional prostate motion using magnetic resonance imagine. Int J Radiat Oncol Biol Phys 54:568-575
49. Malone S, Crook JM, Kendal WS, Szanto J (2000) Respiratory-induced prostate motion: quantification and characterization. Int J Radiat Oncol Biol Phys 48:105-109
50. Martinez AA, Gustagson G, Gonzalez J, Armour E, Mitchell C, Edmundson G, Spencer W, Stromberg J, Huang R, Vicini F (2002) Dose escalation using conformal high-dose-rate brachytherapy improves outcome in unfavorable prostate cancer. Int J Radiat Oncol Biol Phys 53:316-327
51. Nederveen AJ, Lagendijk JJ, Hofman P (2001) Feasibility of automatic marker detection with an a-Si flat-panel imager. Phys Med Biol 46:1219-1230
52. Nederveen AJ, van der Heide UA, Dehnad H, van Moorselaar RJ, Hofman P, Lagendijk JJ (2002) Measurements and clinical consequences of prostate motion during a radiotherapy fraction. Int J Radiat Oncol Biol Phys 53:206-214
53. Perez CA, Pilepich MV, Garcia D, Simpson JR, Zivnuska F, Hederman MA (1988) Definitive radiation therapy in carcinoma of the prostate localized to the pelvis: experience at the Mallinckrodt Institute of Radiology. NCI Monographs 7:85-94
54. Perez CA, Michalski JM, Lockett MA (2001) Chemical disease-free survival in localized carcinoma of prostate treated with external beam irradiation: comparison of American Society of Therapeutic Radiology and Oncology Consensus or 1 ng/mL as endpoint. Int J Radiat Oncol Biol Phys 49:1287-1296
55. Pinover W, Hanlon A, Hanks G, Horwitz E (2000) Defining the appropriate radiation dose for pretreatment PSA < / = 10 ng/ml prostate cancer. Int J Radiat Oncol Biol Phys 47:649-654
56. Pollack A, Hanlon AL, Movsas B, Hanks GE, Uzzo RG, Horwitz EM (2003) Biochemical failure as a determinant of distant metastasis and death In prostate cancer treated with radiotherapy. Int J Radiat Oncol Biol Phys, in press
57. Pollack A, Zagars GK, Antolak JA, Kuban DA, Rosen II (2002) Prostate biopsy status and PSA nadir level as early surrogates for treatment failure: analysis of a prostate cancer randomized radiation dose escalation trial. Int J Radiat Oncol Biol Phys 54:677-685
58. Pollack A, Smith L, von Eschenbach A (2000) External beam radiotherapy dose-response characteristics of 1127 men with prostate cancer treated in the PSA era. Int J Radiat Oncol Biol Phys 48:507-512
59. Pollack A, Kuban DA, Zagars GK (2002) Impact of androgen deprivation therapy on survival in men treated with radiation for prostate cancer. Urology 60:22-30
60. Pollack A, Zagars GK, Starkschall G, Antolak JA, Lee JJ, Huang E, von Eschenbach AC, Kuban DA, Rosen I (2002) Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 53:1097-1105
61. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Phil D, Urie MM, McManus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, Heney NM, Goitein M (1995) Advanced prostate cancer: the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone. Int J Radiat Oncol Biol Phys 32:3-12
62. Sidhu K, Ford EC, Spirou S, Yorke E, Chang J, Mueller K, Todor D, Rosenzweig K, Mageras G, Chui C, Ling CC, Amols H (2003) Optimization of conformal thoracic radiotherapy using cone-beam CT imaging for treatment verification. Int J Radiat Oncol Biol Phys 55:757-767
63. Skwarchuk MW, Jackson A, Zelefsky MJ, Venkatraman ES, Cowen DM, Levegrun S, Burman CM, Fuks Z, Leibel SA, Ling CC (2000) Late rectal toxicity after conformal radiotherapy of prostate cancer (I): multivariate analysis and dose-response. Int J Radiat Oncol Biol Phys 47:103-113
64. Teh BS, McGary JE, Dong L, Mai WY, Carpenter LS, Lu HH, Chiu JK, Woo SY, Grant WH, Butler EB (2002) The use of rectal balloon during the delivery of intensity modulated radiotherapy (IMRT) for prostate cancer: more than just a prostate gland immobilization device? Cancer J 8:476-483
65. Uematsu M, Shioda A, Suda A, Fukui T, Ozeki Y, Hama Y, Wong JR, Kusano S (2001) Computed tomography-guided frameless stereotactic radiotherapy for stage I non-small cell lung cancer: a 5-year experience. Int J Radiat Oncol Biol Phys 51:666-670
66. Wu J, Haycocks T, Alasti H, Ottewell G, Middlemiss N, Abdolell M, Warde P, Toi A, Catton C (2001) Positioning errors and prostate motion during conformal prostate radiotherapy using on-line isocentre set-up verification and implanted prostate markers. Radiother Oncol 61:127-133
67. Zagars GK, Pollack A, Kavadi VS, von Eschenbach AC (1995) Prostate-specific antigen and radiation therapy for clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 32:293-306
68. Zelefsky M, Leibel S, Gaudin P, Kutcher G, Fleshner N, Venkatramen E, Reuter V, Fair W, Ling C, Fuks Z (1998) Dose escalation with three-dimensional conformal radiation therapy affects the outcome in prostate cancer. Int J Radiat Oncol Biol Phys 41:491-500
69. Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA (2001) High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer. J Urol 166:876-881
70. Zelefsky MJ, Fuks Z, Hunt M, Yamada Y, Marion C, Ling CC, Amols H, Venkatraman ES, Leibel SA (2002) High-dose intensity modulated radiation therapy for prostate cancer: early toxicity and biochemical outcome in 772 patients. Int J Radiat Oncol Biol Phys 53:1111-1116